Latest news and press releases about Gelteq Limited Ordinary Shares (GELS): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Gelteq Limited, established in 2017 and based in Caulfield, Australia, specializes in creating and commercializing advanced gel-based delivery methods for both human and animal use. The company offers customizable, white-label gel formulations that can be applied to a broad array of goods, such as prescribed pharmaceuticals, non-prescription remedies, nutritional supplements (including sports-related products), and veterinary care items.
Price
| Price | $0.58 |
| Market Cap | $5M |
| Exchange | NASDAQ |
| Country | AU |
Valuation Ratios
| Price / Book | 0.59 |
| EV / EBITDA | -5.67 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -24.94% |
| Return on Invested Capital | -18.33% |
| Return on Assets | -18.59% |
| Gross Margin | 100.00% |
| Operating Margin | -1986.04% |
| Net Margin | -2095.34% |
Related companies: AYTU · BFRG · BFRI · BGLC · COCP · EVGN · IMNN
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of GELS: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks